On March 6, 2013 encouraging results from a study involving rheumatoid arthritis medications were published. This study, available in the March 6 issue of the Journal of the American Medical Association, reassured patients who are taking the newest medications. Results concluded from this particular study revealed that these drugs do not appear to raise the[…]
Breaking News: No Heightened Risk of Shingles for Patients Taking Newer Rheumatoid Arthritis Medications
Anti-Inflammatory, Anti-Psoriatic, Drug Research & Development API, Monoclonal Antibodies / mAb Tags: 331731-18-1AdalimumabEtanerceptHumiraRheumatoid ArthritisRituximab Mar 18, 2013
Infrequent Dosing of Ustekinumab is Appealing to Patients with Plaque Psoriasis
Drug Research & Development API, Monoclonal Antibodies / mAb Tags: Etanerceptplaque psoriasis Mar 14, 2012
Ustekinumab, CAS number 815610-63-0, is also known by it’s brand name Stelara, which is marketed by Janssen Biotech, Inc. Developed as a treatment for adults with moderate to severe plaque psoriasis, which may involve vast areas of their body, Stelara is unique in it’s dosing. Stelara, or ustekinumab, is typically given twice in the first[…]
Etanercept Offers Relief for Patients with Rheumatoid Arthritis
Anti-Inflammatory, Anti-Psoriatic, Drug Research & Development API Tags: Etanerceptplaque psoriasisRheumatoid Arthritis Mar 13, 2012
Etanercept, known by the trade name Enbrel, is indicated for reducing the signs and symptoms of Rheumatoid Arthritis. In addition, etanercept, CAS number 185243-69-0, is effective in reduction of symptoms as related to Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Plaque Psoriasis. Developed by researchers at Immunex, etanercept is marketed as Enbrel by[…]
